The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes.
AMA J Ethics. 2017;19(2):192-198. doi:
10.1001/journalofethics.2017.19.2.pfor2-1702.
Legacy patients are so-called because their opioid use behaviors express past, aggressive opioid prescribing by a clinician. Managing their pain and dependence justly is ethically complex.
AMA J Ethics. 2020;22(8):E651-657. doi:
10.1001/amajethics.2020.651.
Marissa Chaet Brykman, JD, Virginia Streusand Goldman, PhD, Nandakumara Sarma, PhD, RPh, Hellen A. Oketch-Rabah, PhD, MSc, Deborah Biswas, JD, and Gabriel I. Giancaspro, PhD
Increase in dietary supplement use in the United States suggests a great need for clinicians to be aware of the range of their quality parameters.
AMA J Ethics. 2022;24(5):E382-389. doi:
10.1001/amajethics.2022.382.
Marissa Chaet Brykman joins Ethics Talk to discuss her article, coauthored with Dr Virginia Streusand Goldman, Dr Nandakumara Sarma, Dr Hellen A. Oketch-Rabah, Deborah Biswas and Dr Gabriel I. Giancaspro: “What Should Clinicians Know About Dietary Supplement Quality?”
Dr Ilisa B. G. Bernstein joins Ethics Talk to discuss her article, coauthored with Karin L. Bolte: “Is My Patient Taking an Unsafe Dietary Supplement?”
Elizabeth Richardson joins Ethics Talk to discuss her article, coauthored Farzana Akkas and Dr Amy B. Cadwallader: “What Should Dietary Supplement Oversight Look Like in the US?”
Dr Alexander Ding joins Ethics Talk to discuss his article, coauthored with Dr Amy B. Cadwallader and other members of the AMA Council on Science and Public Health: “Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention?”